CN1997390A - 微流化水包油乳状液和疫苗组合物 - Google Patents
微流化水包油乳状液和疫苗组合物 Download PDFInfo
- Publication number
- CN1997390A CN1997390A CNA2005800119857A CN200580011985A CN1997390A CN 1997390 A CN1997390 A CN 1997390A CN A2005800119857 A CNA2005800119857 A CN A2005800119857A CN 200580011985 A CN200580011985 A CN 200580011985A CN 1997390 A CN1997390 A CN 1997390A
- Authority
- CN
- China
- Prior art keywords
- oil
- preparation
- vaccine
- amphigen
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
治疗组 | 佐剂组成 |
T01 | 盐水 |
T02 | Quil-A、胆固醇、和AMPHIGEN制剂(QAC) |
T03 | Quil-A、胆固醇、AMPHIGEN制剂和AlOH(QAC-AlOH) |
T04 | DDA、胆固醇、和AMPHIGEN制剂(DDA) |
T05 | DDA、胆固醇、AMPHIGEN制剂和AlOH(DDA-AlOH) |
处理 | 在培养中,在尿液和肾脏中对钩端螺旋体呈阳性的小牛百分比 | 在FA中,尿液和肾脏中对钩端螺旋体呈阳性的小牛百分比 | 在PCR中,尿液和肾脏中对钩端螺旋体呈阳性的小牛百分比 | 在所有化验中,尿液和肾脏中对钩端螺旋体呈阳性的小牛百分比 |
盐水 | 100 | 83.3 | 83.3 | 100 |
QAC | 0 | 0 | 0 | 0 |
QAC/AlOH | 0 | 50.0 | 0 | 50.0 |
DDA | 0 | 0 | 0 | 0 |
DDA/AlOH | 0 | 33.3 | 16.7 | 50.0 |
处理 | L.Hardjo | L.pomona |
盐水 | <20 | <20 |
QAC | 160-640 | 1280-10240 |
QAC/AlOH | 160-2560 | 8--10240 |
DDA | 40-1280 | 320-2560 |
DDA/AlOH | 320-640 | 1280-5120 |
治疗组 | 佐剂组成 |
T01 | 盐水 |
T02 | Quil-A、AMPHIGEN制剂、和胆固醇 |
T03 | AMPHIGEN制剂、胆固醇、DDA(0.5毫克/剂)和AlOH |
T04 | AMPHIGEN制剂、胆固醇、和DDA(0.5毫克/剂) |
T05 | AMPHIGEN制剂、胆固醇、和DDA(1.0毫克/剂) |
T06 | AMPHIGEN制剂、胆固醇、和DDA(2.0毫克/剂) |
处理 | 研究日BVDv1型几何平均SVN滴度 | |||||
0 | 21 | 35 | 44 | 58 | ||
T01 | 盐水 | <2 | <2 | <2 | <2 | 23.9 |
T02 | Amphigen,QuiI A | <2 | 39.1 | 19824.5 | 14018.2 | 27554.5 |
T03 | Amphigen,0.5mgDDA,Al | <2 | 51.8 | 32204.8 | 22381.1 | 23170.4 |
T04 | Amphigen,0.5mgDDA | <2 | 27.0 | 14512.4 | 8932.0 | 21996.2 |
T05 | Amphigen,1.0mgDDA | <2 | 26.7 | 11585.2 | 8194.6 | 20882.0 |
T06 | Amphigen,2.0mgDDA | <2 | 23.5 | 8778.7 | 6769.3 | 16961.1 |
处理 | 研究日BVDv1型几何平均SVN滴度 | |||||
0 | 21 | 35 | 44 | 58 | ||
T01 | 盐水 | <2 | <2 | <2 | <2 | 522.0 |
T02 | Amphigen,Quil A | <2 | 8.9 | 2272.4 | 2048.2 | 24833.6 |
T03 | Amphigen,0.5mgDDA,Al | <2 | 9.5 | 3565.7 | 2702.2 | 20881.8 |
T04 | Amphigen,0.5mg DDA | <2 | 4.1 | 1260.7 | 989.1 | 18496.2 |
T05 | Amphigen,1.0mgDDA | <2 | 6.4 | 1398.8 | 1453.9 | 30047.8 |
T06 | Amphigen,2.0mg DDA | <2 | 7.7 | 1673.2 | 1428.9 | 16384.0 |
处理 | BVD病毒分离 | |||
研究日 | 患病毒血症动物的频率(%) | 具有病毒血症的LSMean天数 | ||
T01 | 盐水 | 47至58 | 10/10(100.0) | 10.4 |
T02 | Amphigen,Quil A | 50至53 | 1/10(10.0) | 0.4 |
T03 | Amphigen,0.5mg DDA,Al | --- | 0/10(0.0) | 0.0 |
T04 | Amphigen,0.5mg DDA | 48,50至52,57 | 3/10(30.0) | 0.5 |
T05 | Amphigen,1.0mg DDA | 49至51 | 2/10(20.0) | 0.4 |
T06 | Amphigen,2.0mg DDA | 48至52 | 2/10(20.0) | 0.5 |
处理 | 疾病发病率(%) | 观察到BVD病临床体征的频率(%) | 总共Obs. | ||||
0 | 1 | 2 | 3 | ||||
T01 | 盐水 | 9/10(90.0) | 75(46) | 63(37.5) | 29(17.3) | 1(0.6) | 168 |
T02 | Amphigen,QuilA | 1/10(10.0) | 105(61.8) | 63(37.1) | 2(1.2) | 0(0) | 170 |
T03 | Amphigen,0.5mgDDA,Al | 2/10(20.0) | 99(58.2) | 67(39.4) | 4(2.4) | 0(0) | 170 |
T04 | Amphigen,0.5mg DDA | 0/10(0.0) | 118(69.4) | 52(30.6) | 0(0) | 0(0) | 170 |
T05 | Amphigen,1.0mg DDA | 0/10(0.0) | 101(59.4) | 69(40.6) | 0(0) | 0(0) | 170 |
T06 | Amphigen,2.0mg DDA | 0/10(0.0) | 104(61.2) | 66(38.8) | 0(0) | 0(0) | 170 |
处理 | 白细胞减少症 | ||
患白细胞减少症的动物的频率(%) | 具有白细胞减少症的LSMean天数 | ||
T01 | 盐水 | 10/10(100.0) | 7.8 |
T02 | Amphi gen,Quil A | 6/10(60.0) | 1.2 |
T03 | Amphigen,0.5mg DDA,Al | 2/10(20.0) | 0.2 |
T04 | Amphigen,0.5mg DDA | 4/10(40.0) | 0.8 |
T05 | Amphigen,1.0mg DDA | 3/10(30.0) | 0.9 |
T06 | Amphigen,2.0mg DDA | 2/10(30.0) | 0.5 |
处理 | 研究日的平均体重(lb.) | 体重增加(lb) | ||||
-1 | 43 | 50 | 58 | |||
T01 | 盐水 | 378.0 | 484.9 | 491.0 | 476.9 | 98.9 |
T02 | Amphigen,Quil A | 428.0 | 526.5 | 546.7 | 579.0 | 151.0 |
T03 | Amphigen,0.5mgDDA,AlOH | 410.5 | 514.4 | 534.2 | 579.0 | 168.5 |
T04 | Amphigen,0.5mg DDA | 373.7 | 472.3 | 492.6 | 538.1 | 164.4 |
T05 | Amphigen,1.0mg DDA | 358.9 | 451.4 | 478.9 | 507.1 | 148.2 |
T06 | Amphigen,2.0mg DDA | 408. | 513.3 | 533.9 | 560.3 | 151.6 |
处理 | 几何平均SVN滴度 | |||||
0 | 21 | 35 | 43 | 57 | ||
T01 | 盐水 | <2 | <2 | <2 | <2 | 35.5 |
T02 | Amphigen,Quil A | <2 | 98.7 | 20171.0 | 12203.4 | 44762.4 |
T03 | Amphigen,2mgGPI-0100,AlOH | <2 | 84.6 | 10998.5 | 7383.2 | 25709.2 |
T04 | Amphigen,2mgGPI-0100 | <2 | 106.0 | 18179.2 | 8933.2 | 28526.2 |
T05 | Amphigen,3mgGPI-0100 | <2 | 62.9 | 15024.3 | 8780.1 | 19824.4 |
T06 | Amphigen,5mgGPI-0100 | <2 | 71.1 | 12203.3 | 7512.0 | 16670.2 |
处理 | 研究日BVDv1型几何平均SVN滴度 | |||||
0 | 21 | 35 | 44 | 58 | ||
T01 | 盐水 | <2 | <2 | <2 | <2 | 14.7 |
T02 | Amphigen,Quil A | <2 | 12.9 | 2312.0 | 1692.5 | 1663.4 |
T03 | Amphigen,2mg GPI-0100,AlOH | <2 | 13.2 | 1663.5 | 1116.8 | 1562.3 |
T04 | Amphigen,2mg GPI-0100 | <2 | 20.5 | 2610.2 | 1978.2 | 2478.7 |
T05 | Amphjgen,3mg GPI-0100 | <2 | 11.4 | 1752.8 | 1305.2 | 2435.4 |
T06 | Amphigen,5mg GPI-0100 | <2 | 12.0 | 3158.4 | 2120.2 | 1845.6 |
处理 | BVD病毒分离 | ||
患病毒血症动物的频率(%) | 具有病毒血症的LSMean天数 | ||
T01 | 盐水 | 10/10(100.0) | 8.4 |
T02 | Amphigen,Quil A | 3/10(30.0) | 0.3 |
T03 | Amphigen,2mg GPI-0100,AlOH | 0/10(0.0) | 0.0 |
T04 | Amphigen,2mg GPI-0100 | 1/10(10.0) | 0.1 |
T05 | Amphigen,3mg GPI-0100 | 3/10(30.0) | 0.3 |
T06 | Amphigen,5mg GPI-0100 | 2/10(20.0) | 0.2 |
处理 | 患病频率(%) | 观察具有下列临床疾病评分的频率(%) | 总共Obs. | |||
0 | 1 | 2 | ||||
T01 | 盐水 | 5/10(50.0) | 103(60.6) | 55(32.4) | 12(7.1) | 170 |
T02 | Amphigen,Quil A | 5/10(50.0) | 115(67.6) | 48(28.2) | 7(4.1) | 170 |
T03 | Amphigen,2mgGPI-0100,AlOH | 0/10(0.0) | 128(75.3) | 42(24.7) | 0(0) | 170 |
T04 | Amphigen,2mgGPI-0100 | 0/10(0.0) | 124(72.9) | 46(27.1) | 0(0) | 170 |
T05 | Amphigen,3mgGPI-0100 | 0/10(0.0) | 104(61.2) | 66(38.8) | 0(0) | 170 |
T06 | Amphigen,5mgGPI-0100 | 0/10(0.0) | 128(75.3) | 42(24.7) | 0(0) | 170 |
处理 | 白细胞减少症 | ||
患白细胞减少症的动物的频率(%) | 患白细胞减少症的LSMean天数 | ||
T01 | 盐水 | 9/10(90.0) | 8.7 |
T02 | QuilA | 6/10(60.0) | 1.6 |
T03 | 2mg GPI-0100,AlOH | 7/10(70.0) | 2.6 |
T04 | 2mg GPI-0100 | 4/10(40.0) | 1.5 |
T05 | 3mg GPI-0100 | 7/10(70.0) | 2.6 |
T06 | 5mg GPI-0100 | 8/10(80.0) | 2.9 |
处理 | 抗原 | 佐剂 |
T01 | 安慰剂 | 盐水 |
T02 | Pau A/E.coli | SEAM-14 |
T03 | Pau A/E.coli | 2.5%Amphigen,0.5毫克GPI-0100,0.5毫克胆固醇 |
T04 | Pau A/E.coli | 2.5%Amphigen,0.5毫克溴化二甲基双十八烷基铵(DDA),0.5毫克胆固醇 |
系列 | BRSV | BHV | PI3 |
A | 0 | 0.2 | 0 |
AM200 | -0.2 | 0 | -0.2 |
AM75 | 0 | -0.3 | -0.3 |
AM75@37C | 0.1 | -0.3 | -0.2 |
B | 0 | -0.1 | -0.2 |
BM200 | 0 | 0 | -0.2 |
BM75 | -0.2 | -0.5 | 0 |
BM75@37C | 0.5 | -0.5 | 0 |
C | 0.1 | -0.1 | -0.2 |
CM200 | -0.2 | -0.1 | -0.2 |
CM75 | 0.1 | 0.5 | -0.2 |
CM75@37C | 0.5 | 0.5 | -0.2 |
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55967704P | 2004-04-05 | 2004-04-05 | |
US60/559,677 | 2004-04-05 | ||
PCT/IB2005/000804 WO2005097181A1 (en) | 2004-04-05 | 2005-03-24 | Microfluidized oil-in-water emulsions and vaccine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1997390A true CN1997390A (zh) | 2007-07-11 |
CN1997390B CN1997390B (zh) | 2012-10-10 |
Family
ID=34961993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800119857A Active CN1997390B (zh) | 2004-04-05 | 2005-03-24 | 微流化水包油乳状液和疫苗组合物 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7122191B2 (zh) |
EP (2) | EP1742659B1 (zh) |
JP (2) | JP5393978B2 (zh) |
KR (5) | KR101143060B1 (zh) |
CN (1) | CN1997390B (zh) |
AR (1) | AR048822A1 (zh) |
AU (1) | AU2005230708B2 (zh) |
BR (1) | BRPI0509606B1 (zh) |
CA (1) | CA2561914C (zh) |
DK (1) | DK1742659T3 (zh) |
ES (1) | ES2409782T3 (zh) |
HK (1) | HK1108830A1 (zh) |
NO (1) | NO341034B1 (zh) |
NZ (1) | NZ550152A (zh) |
PL (1) | PL1742659T3 (zh) |
PT (1) | PT1742659E (zh) |
RU (1) | RU2347586C2 (zh) |
SI (1) | SI1742659T1 (zh) |
TW (1) | TWI301067B (zh) |
UA (1) | UA89631C2 (zh) |
UY (1) | UY28840A1 (zh) |
WO (1) | WO2005097181A1 (zh) |
ZA (1) | ZA200608200B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926994A (zh) * | 2010-08-19 | 2010-12-29 | 中国医学科学院医学生物学研究所 | 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗 |
CN104013955A (zh) * | 2014-06-18 | 2014-09-03 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
CN108697782A (zh) * | 2016-03-23 | 2018-10-23 | 英特维特国际股份有限公司 | 针对pcv2病毒和猪肺炎支原体感染的组合疫苗 |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39494E1 (en) * | 1992-02-27 | 2007-02-27 | Intervet Inc. | Inactivated mycoplasma hyopneumoniae and uses therefor |
EP1333858B8 (en) | 2000-11-07 | 2006-06-14 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
AR044732A1 (es) * | 2002-11-08 | 2005-10-05 | H P B S A | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
WO2005097181A1 (en) * | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
BRPI0612669B8 (pt) | 2005-06-27 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, composição, e composição liofilizada |
US20070042001A1 (en) * | 2005-08-16 | 2007-02-22 | Hawaii Biotech, Inc. | Influenza recombinant subunit vaccine |
WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
CA2628206A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
PL2368572T3 (pl) | 2005-11-04 | 2020-11-16 | Seqirus UK Limited | Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej |
EP1792619A1 (en) * | 2005-11-28 | 2007-06-06 | Laboratorios Maymo, S.A. | Beta-sitosterol for treating porcine respiratory disease complex |
BRPI0707300B8 (pt) | 2006-01-27 | 2021-05-25 | Novartis Ag | vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica |
EP1988918A4 (en) * | 2006-02-22 | 2010-04-28 | Novavax Inc | ADJUVANZ AND VACCINE COMPOSITIONS |
WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
AU2007330494B2 (en) | 2006-12-06 | 2014-03-13 | Seqirus UK Limited | Vaccines including antigen from four strains of influenza virus |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
AU2008303023B2 (en) | 2007-09-27 | 2014-01-09 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
BR122016015627A2 (pt) | 2007-10-19 | 2018-10-30 | Novartis Ag | kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
US20110014230A1 (en) | 2008-03-18 | 2011-01-20 | Novartis Ag | preparation of influenza virus vaccine antigens |
PL2276495T3 (pl) | 2008-04-17 | 2019-05-31 | Pds Biotechnology Corp | Stymulacja odpowiedzi układu immunologicznego przez enancjomery kationowych lipidów |
TWI551295B (zh) * | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | 防備胞內勞森菌(Lawsonia intracellularis)用疫苗 |
EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
MX368220B (es) * | 2008-06-27 | 2019-09-24 | Zoetis Services Llc | Composiciones adyuvantes novedosas. |
AU2012258478B2 (en) * | 2008-06-27 | 2013-10-03 | Zoetis Services Llc | Novel adjuvant compositions |
NZ591768A (en) | 2008-09-18 | 2012-11-30 | Novartis Ag | Vaccine adjuvant combinations |
JP5642712B2 (ja) | 2009-02-10 | 2014-12-17 | ノバルティス アーゲー | 少ない量のスクアレンを含むインフルエンザワクチン |
CN102438651A (zh) | 2009-02-10 | 2012-05-02 | 诺华有限公司 | 用于大流行相关毒株的流感疫苗方案 |
AU2010212548A1 (en) | 2009-02-10 | 2011-09-15 | Novartis Ag | Influenza vaccines with increased amounts of H3 antigen |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
EP2411045A1 (en) | 2009-03-24 | 2012-02-01 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
SG175092A1 (en) | 2009-04-14 | 2011-11-28 | Novartis Ag | Compositions for immunising against staphylococcus aerus |
PT2401384E (pt) | 2009-05-21 | 2012-12-19 | Novartis Ag | Genética reversa com recurso a promotores da pol i não endógenos |
WO2010136896A1 (en) | 2009-05-29 | 2010-12-02 | Novartis Ag | Assays for influenza virus hemagglutinins |
JP2012532600A (ja) | 2009-07-07 | 2012-12-20 | ノバルティス アーゲー | 保存された大腸菌免疫原 |
EP4218800A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
AU2010272243A1 (en) | 2009-07-16 | 2012-03-08 | Novartis Ag | Detoxified Escherichia coli immunogens |
US9821052B2 (en) | 2009-07-31 | 2017-11-21 | Seqirus UK Limited | Reverse genetics systems |
EP2464341B1 (en) * | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
WO2011030218A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
ES2454815T3 (es) | 2009-10-20 | 2014-04-11 | Novartis Ag | Métodos mejorados de genética inversa para la recuperación de virus |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
WO2011056226A1 (en) * | 2009-11-05 | 2011-05-12 | Mercia Pharma Llc | Adjuvanted nanoparticulate influenza vaccine |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
BR112012013427B8 (pt) | 2009-12-03 | 2021-05-25 | Novartis Ag | circulação dos componentes durante a homogeneização de emulsões |
DE102009056884B4 (de) * | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
BR112012013425A2 (pt) | 2009-12-03 | 2020-11-03 | Novartis Ag | filtração hidrofílica durante a fabricação de adjuvantes de vacinas |
DE102009056871A1 (de) * | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
DE102009056883B4 (de) * | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
EP2519265B1 (en) | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | Polysaccharide immunogens conjugated to e. coli carrier proteins |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
US20130071422A1 (en) | 2010-03-18 | 2013-03-21 | Michele Pallaoro | Adjuvanted vaccines for serogroup b meningococcus |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
CA2800150C (en) | 2010-05-21 | 2018-09-04 | Novartis Ag | Influenza virus reassortment method |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
DK2667892T3 (da) | 2011-01-26 | 2019-05-13 | Glaxosmithkline Biologicals Sa | RSV-vaccineringsprogram |
BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
LT2707385T (lt) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Iš anksto sulieti rsv f antigenai |
EP2729178A1 (en) | 2011-07-08 | 2014-05-14 | Novartis AG | Tyrosine ligation process |
CN103917245B (zh) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | 用于制备糖‑蛋白质糖缀合物的方法 |
SG11201401177WA (en) | 2011-10-06 | 2014-04-28 | Immunovaccine Technologies Inc | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
MX354924B (es) | 2011-11-07 | 2018-03-22 | Novartis Ag | Molecula portadora que comprende un antigeno spr0096 y un spr2021. |
EP3023790A1 (en) | 2011-12-12 | 2016-05-25 | Novartis AG | Assay for influenza virus hemagglutinins |
WO2013092985A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Stable compositions for immunising against staphylococcus aureus |
CA2813723A1 (en) | 2012-03-02 | 2013-09-02 | Novartis Ag | Influenza virus reassortment |
JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
CN104582723A (zh) | 2012-08-31 | 2015-04-29 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质 |
WO2014033190A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
AU2013320313B2 (en) | 2012-09-18 | 2018-07-12 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
CN105101991A (zh) | 2012-09-21 | 2015-11-25 | Pds生物科技公司 | 改进的疫苗组合物和使用方法 |
BR112015007126A2 (pt) | 2012-10-02 | 2017-08-08 | Glaxosmithkline Biologicals Sa | composição, método para induzir uma resposta imune, e, uso de uma composição |
AR092939A1 (es) | 2012-10-09 | 2015-05-06 | Univ Gent | Vacuna contra cooperia |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
CA2886938A1 (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
ES2656510T3 (es) | 2012-11-30 | 2018-02-27 | Glaxosmithkline Biologicals S.A. | Antígenos de Pseudomonas y combinación de antigenos |
JP6421128B2 (ja) | 2012-12-03 | 2018-11-07 | ノバルティス アーゲー | リアソータントインフルエンザaウイルス |
UY34506A (es) | 2012-12-10 | 2014-06-30 | Fernando Amaury Ferreira Chiesa | Adyuvante de vacunación, preparación y vacunas que lo contienen |
EP2934574A1 (en) | 2012-12-18 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Conjugates for protecting against diphtheria and/or tetanus |
US10232031B2 (en) | 2013-03-13 | 2019-03-19 | Seqirus UK Limited | Influenza virus reassortment |
WO2014180999A1 (en) | 2013-05-10 | 2014-11-13 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
MX2015016755A (es) | 2013-06-06 | 2016-04-13 | Novartis Ag | Reagrupamiento del virus de influenza. |
CA2924526A1 (en) | 2013-09-19 | 2015-03-26 | Paul Joseph Dominowski | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
US20160256540A1 (en) | 2013-10-17 | 2016-09-08 | Zoetis Services Llc | Methods And Compositions For Treatment Of S. Equi Infection |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
US11318200B2 (en) * | 2013-11-26 | 2022-05-03 | Zoetis Services Llc | Methods and compositions for induction of immune response |
US10280199B2 (en) | 2014-02-07 | 2019-05-07 | Phibro Animal Health Corporation | Coronavirus proteins and antigens |
EA037818B1 (ru) | 2014-03-26 | 2021-05-25 | Глаксосмитклайн Байолоджикалс С.А. | Мутантные стафилококковые антигены |
MX2017009306A (es) | 2015-01-16 | 2017-11-08 | Zoetis Services Llc | Vacuna contra la fiebre aftosa. |
EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
JP6830070B2 (ja) | 2015-07-07 | 2021-02-17 | セキラス ユーケー リミテッドSeqirus UK Limited | インフルエンザ効力アッセイ |
EP4092112A1 (en) | 2015-11-13 | 2022-11-23 | PDS Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
EP3454891A4 (en) * | 2016-05-10 | 2019-12-25 | The Regents of The University of Michigan | EMULSION ADDITIVE FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION |
US10279031B2 (en) | 2016-05-11 | 2019-05-07 | Phibro Animal Health Corporation | Composition comprising antigens and a mucosal adjuvant and a method for using |
EP3454893A4 (en) * | 2016-05-11 | 2020-01-01 | Phibro Animal Health Corporation | COMPOSITION WITH ANTIGENS AND A MUCUTINE ADJUVAN AND METHOD FOR USE |
US11547672B2 (en) | 2018-09-14 | 2023-01-10 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
EP3914708A1 (en) | 2019-01-24 | 2021-12-01 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
US20230190920A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
WO2023154960A1 (en) | 2022-02-14 | 2023-08-17 | University Of Georgia Research Foundation, Inc. | Pan-pneumovirus vaccine compositions and methods of use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310550A (en) | 1979-10-26 | 1982-01-12 | Pfizer Inc. | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
US4908154A (en) | 1981-04-17 | 1990-03-13 | Biotechnology Development Corporation | Method of forming a microemulsion |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5690942A (en) | 1995-06-02 | 1997-11-25 | American Home Products Corporation | Adjuvants for viral vaccines |
US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
ES2201551T3 (es) * | 1997-09-05 | 2004-03-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE60017211T2 (de) * | 1999-02-17 | 2005-06-02 | Pfizer Products Inc., Groton | Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren |
ATE276758T1 (de) * | 1999-04-19 | 2004-10-15 | Glaxosmithkline Biolog Sa | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
DE10106446A1 (de) * | 2001-02-09 | 2002-10-10 | Haarmann & Reimer Gmbh | Verfahren zur Herstellung blauer Mikrokapseln |
WO2004017990A1 (en) * | 2002-08-26 | 2004-03-04 | Pfizer Products Inc. | Vaccine for respiratory and reproductive system infections in cattle |
PL378001A1 (pl) * | 2003-01-29 | 2006-02-20 | Pfizer Products Inc. | Szczepionki przeciw Bordetella bronchiseptica dla psów |
CA2521051C (en) * | 2003-04-04 | 2012-03-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
WO2005097181A1 (en) * | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
-
2005
- 2005-03-24 WO PCT/IB2005/000804 patent/WO2005097181A1/en active Application Filing
- 2005-03-24 CA CA2561914A patent/CA2561914C/en active Active
- 2005-03-24 EP EP20050718292 patent/EP1742659B1/en active Active
- 2005-03-24 CN CN2005800119857A patent/CN1997390B/zh active Active
- 2005-03-24 DK DK05718292T patent/DK1742659T3/da active
- 2005-03-24 NZ NZ550152A patent/NZ550152A/en unknown
- 2005-03-24 RU RU2006135121A patent/RU2347586C2/ru active
- 2005-03-24 EP EP20100178441 patent/EP2269644A3/en not_active Withdrawn
- 2005-03-24 BR BRPI0509606A patent/BRPI0509606B1/pt active IP Right Grant
- 2005-03-24 KR KR1020087031330A patent/KR101143060B1/ko active IP Right Grant
- 2005-03-24 SI SI200531727T patent/SI1742659T1/sl unknown
- 2005-03-24 KR KR1020117022798A patent/KR20110132416A/ko not_active Application Discontinuation
- 2005-03-24 UA UAA200610518A patent/UA89631C2/ru unknown
- 2005-03-24 KR KR1020097009238A patent/KR20090051129A/ko not_active Application Discontinuation
- 2005-03-24 ES ES05718292T patent/ES2409782T3/es active Active
- 2005-03-24 PL PL05718292T patent/PL1742659T3/pl unknown
- 2005-03-24 PT PT57182925T patent/PT1742659E/pt unknown
- 2005-03-24 JP JP2007506850A patent/JP5393978B2/ja active Active
- 2005-03-24 KR KR1020067020930A patent/KR20070008625A/ko not_active Application Discontinuation
- 2005-03-24 AU AU2005230708A patent/AU2005230708B2/en active Active
- 2005-03-24 KR KR1020087018863A patent/KR20080073376A/ko not_active Application Discontinuation
- 2005-04-01 US US11/096,831 patent/US7122191B2/en active Active
- 2005-04-01 TW TW94110524A patent/TWI301067B/zh active
- 2005-04-04 AR ARP050101316 patent/AR048822A1/es not_active Application Discontinuation
- 2005-04-04 UY UY28840A patent/UY28840A1/es not_active Application Discontinuation
-
2006
- 2006-10-02 ZA ZA200608200A patent/ZA200608200B/xx unknown
- 2006-11-02 NO NO20065039A patent/NO341034B1/no unknown
-
2007
- 2007-12-20 HK HK07113918A patent/HK1108830A1/xx unknown
-
2011
- 2011-04-13 JP JP2011089018A patent/JP2011168605A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926994A (zh) * | 2010-08-19 | 2010-12-29 | 中国医学科学院医学生物学研究所 | 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗 |
CN104013955A (zh) * | 2014-06-18 | 2014-09-03 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
CN104013955B (zh) * | 2014-06-18 | 2016-02-24 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
CN108697782A (zh) * | 2016-03-23 | 2018-10-23 | 英特维特国际股份有限公司 | 针对pcv2病毒和猪肺炎支原体感染的组合疫苗 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1997390B (zh) | 微流化水包油乳状液和疫苗组合物 | |
CN1767854B (zh) | 微流化水包油乳剂及疫苗组合物 | |
MXPA06011569A (en) | Microfluidized oil-in-water emulsions and vaccine compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1108830 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PAH AMERICA 15 CO., LTD. Free format text: FORMER OWNER: PFIZER PROD INC. Effective date: 20130508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: ZOETIS P LLC Free format text: FORMER NAME: PAH AMERICA 15 CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: New jersey, USA Patentee after: Zotis P LLC Address before: American New York Patentee before: PAH USA 15 LLC |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130508 Address after: American New York Patentee after: PAH USA 15 LLC Address before: American Connecticut Patentee before: PFIZER PRODUCTS Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1108830 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SHUOTENG SERVICE LLC Free format text: FORMER OWNER: ZOETIS P LLC Effective date: 20150826 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150826 Address after: New jersey, USA Patentee after: Zoetis Services LLC Address before: New jersey, USA Patentee before: Zotis P LLC |